Deutsche Bank Downgrades Argenx to Hold

Summary

Deutsche Bank downgraded Belgian immunology company Argenx to ‘hold’ from ‘buy’ on valuation grounds after the stock rallied over 40% in two months. The stock reached the brokerage’s price target, which remains unchanged at 655 euros ($768.18). Out of 19 analysts covering the stock, 18 rate it ‘strong buy’ or ‘buy,’ with one rating it ‘hold’ .

Impact Analysis

So basically, Deutsche Bank’s downgrade of Argenx is a classic case of valuation catching up with a stock’s rapid price appreciation. After a 40% rally in just two months, the stock hit Deutsche Bank’s price target, prompting the downgrade to ‘hold’ from ‘buy’ . The interesting part isn’t the downgrade itself—it’s the fact that 18 out of 19 analysts still rate it as a ‘buy’ or ‘strong buy’ . This suggests that while Deutsche Bank is cautious, the broader analyst community remains bullish, likely due to Argenx’s strong earnings and financial health Market Beat+ 2. The market might be underestimating the potential for further upside if Argenx continues to outperform expectations. However, with technical indicators showing a strong upward trend, there might be a short-term opportunity to buy on dips, especially if the stock pulls back due to the downgrade .